MorphoSys AG (MOR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MorphoSys AG (MOR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Germanecki	2/8/2013 10:06:37 AM
	of 421

MorphoSys Completes Sale of AbD Serotec to Bio-Rad January 10, 2013 / 3:30 pm, CET MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the sale of its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has been completed. All assets and liabilities of the AbD Serotec segment of MorphoSys AG as well as all shares of the subsidiaries MorphoSys UK Ltd., MorphoSys AbD GmbH and MorphoSys US, Inc. have been transferred to Bio-Rad. "We are delighted to have reached the closing of the transaction just a few weeks after the announcement was made. With the divestment of AbD Serotec completed, MorphoSys can devote 100% of its attention to building value in its core therapeutics business," commented Jens Holstein, Chief Financial Officer of MorphoSys AG. About MorphoSys: ... morphosys.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next